InvestorWire NewsRoom

Article

DGE 3rd Clinical Trial Agreement Forum to Discuss Important Changes Impacting CTA’S and Remote Monitoring Agreements
August 22, 2022

DGE 3rd Clinical Trial Agreement Forum to Discuss Important Changes Impacting CTA’S and Remote Monitoring Agreements

Professionals and executives of biopharma and medical device companies are invited to attend DGE’s 3rd Clinical Trial Agreement Forum, a virtual online livestream event, on September 29-30, 2022. The conference will discuss how the evolution of the virtual clinical trial landscape requires flexibility when designing and modifying clinical trial agreements (“CTAs”). Clinical trials have seen many changes with the advent of virtual clinical trials, where telemedicine and remote monitoring are used. Changes that impact the CTAs include incorporating cybersecurity language, more complicated indemnification, complexities of third-party contracting, and an increase in remote monitoring. 

The conference will provide insights into novel industry practices and technological trends for successful results as well as speeding up contracting and study start-ups. The event is hosted by Dynamic Global Events (“DGE”), a life science leader in organizing B2B events. The global event company caters to the dynamic informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical devices, and allied industries. 

This DGE forum offers a phenomenal backdrop for discussing and learning important trends, strategies, and challenges faced in negotiating CTAs. Attendees can connect and communicate with industry stalwarts, gaining valuable insights into the latest industry trends regarding patient data and samples through discussions, panels, and more.

Featured topics and discussions at the conference:

  • Understand the biggest hurdles in negotiating CTAs from sites and sponsors
  • Clearly understand the importance and implications of informed consent and future use of patient data and samples
  • Embody cybersecurity language in CTAs and remote monitoring agreements
  • Define the patient injury provision in subcontracts and clinical trial agreements
  • Learn strategies to manage negotiation budgetary restraints and timelines efficiently
  • Understand how to protect IP and reduce risks in indemnification and subject injury

The event starts with the chairperson’s address, to be followed by discussions from eminent industry heads respected for their wide knowledge and experience in their respective fields. It’s critical to fully understand the best practices and associated strategies for success in this ever-changing landscape. 

The event is conducted in a virtual environment where biotech, pharma, and medical device company experts from all over the world can be a part of the event. Understand how better integration between research and clinical care can lead to novel and much more effective contracting strategies. 

To learn more, please visit https://ibn.fm/yoWrN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).